Characteristics of the study group (95 patients)
| Characteristic . | Value . |
|---|---|
| Age at least 60 y, no. (%) | 67 (71) |
| Median age, y | 65 |
| No. female (%) | 29 (31) |
| Hemoglobin level less than 110 g/L, no. (%) | 81 (85) |
| Granulocyte count less than 1.0 × 109/L, no. (%) | 42 (44) |
| Platelet count less than 100 × 109/L, no. (%) | 68 (72) |
| Chromosomal abnormalities present, no. (%) | 53 (56) |
| Bone marrow blasts, no. (%) | |
| Less than 5% | 23 (24) |
| 5%–9% | 29 (31) |
| 10%–19% | 37 (39) |
| 20%–29% | 6 (6) |
| Duration of MDS | |
| 3–6 mo, no. (%) | 13 (14) |
| More than 6 mo, no. (%) | 36 (38) |
| Median, mo | 3.2 |
| Prior therapy, no. (%) | 58 (61) |
| Growth factors | 35 (37) |
| Others | 23 (24) |
| Secondary MDS, no. (%) | 30 (32) |
| Prior therapy for primary malignancy, no. | |
| Chemotherapy | 7 |
| Irradiation | 5 |
| Both/other | 10 |
| Surgery only | 8 |
| Morphology, no. (%) | |
| MDS | 77 (81) |
| CMML | 18 (19) |
| IPSS risk,* no. (%) | |
| Intermediate 1 | 19 (34) |
| Intermediate 2 | 26 (46) |
| High | 11 (20) |
| Not applicable† | 39 |
| Decitabine schedule, no. (%) | |
| 20 mg/m2 intravenously for 5 d | 64 (67) |
| 20 mg/m2 subcutaneously for 5 d | 14 (15) |
| 10 mg/m2 intravenously for 10 d | 17 (18) |
| Characteristic . | Value . |
|---|---|
| Age at least 60 y, no. (%) | 67 (71) |
| Median age, y | 65 |
| No. female (%) | 29 (31) |
| Hemoglobin level less than 110 g/L, no. (%) | 81 (85) |
| Granulocyte count less than 1.0 × 109/L, no. (%) | 42 (44) |
| Platelet count less than 100 × 109/L, no. (%) | 68 (72) |
| Chromosomal abnormalities present, no. (%) | 53 (56) |
| Bone marrow blasts, no. (%) | |
| Less than 5% | 23 (24) |
| 5%–9% | 29 (31) |
| 10%–19% | 37 (39) |
| 20%–29% | 6 (6) |
| Duration of MDS | |
| 3–6 mo, no. (%) | 13 (14) |
| More than 6 mo, no. (%) | 36 (38) |
| Median, mo | 3.2 |
| Prior therapy, no. (%) | 58 (61) |
| Growth factors | 35 (37) |
| Others | 23 (24) |
| Secondary MDS, no. (%) | 30 (32) |
| Prior therapy for primary malignancy, no. | |
| Chemotherapy | 7 |
| Irradiation | 5 |
| Both/other | 10 |
| Surgery only | 8 |
| Morphology, no. (%) | |
| MDS | 77 (81) |
| CMML | 18 (19) |
| IPSS risk,* no. (%) | |
| Intermediate 1 | 19 (34) |
| Intermediate 2 | 26 (46) |
| High | 11 (20) |
| Not applicable† | 39 |
| Decitabine schedule, no. (%) | |
| 20 mg/m2 intravenously for 5 d | 64 (67) |
| 20 mg/m2 subcutaneously for 5 d | 14 (15) |
| 10 mg/m2 intravenously for 10 d | 17 (18) |